Provider Remittance Advices
We are aware of provider remittance advices not populating into your portal. We are actively working on getting this resolved.
P F
1 de mayo de 2020

Lifespan employee group – Specialty Drug change effective 05/01

Effective 1 de mayo de 2020, Lifespan employee group will begin covering medical specialty drugs under the medical benefit of their members BCBSRI health plan. Any of the drugs requiring prior authorization should be submitted to Prime Therapeutics for review, this includes requests for services to be rendered in a physician’s office, which previously were not reviewed by Prime.

Medical Drug Review (MDR) Specialty Drugs
Actemra
Aldurazyme
Benlysta - IV
Botox
Cerezyme
Cimzia
Cinqair
Dysport
Elaprase
Elelyso
Eylea
Fabrazyme
Fasenra
Flolan
Fulphila
Granix
Krystexxa
Leukine
Lucentis
Lumizyme
Macugen
Makena
Mepsevii
Myobloc
Myozyme
Naglazyme
Neulasta
Neupogen
Nivestym
Nucala
Orencia
Prolia
Remodulin
Rituxan
Sandostatin LAR
Simponi Aria
Somatuline Depot
Somavert
Stelara IV
Synagis
Truxima (rituximab abbs)
Tysabri
Udenyca (pegfilgrastim-cbqv)
Veletri
Vimizim
Visudyne
Vpriv
Xeomin
XGEVA
Xiextenzo
Xolair
Zarxio
Powered by Translations.com GlobalLink OneLink SoftwarePowered By OneLink